St. Jude Medical, Inc. (NYSE:STJ) today announced it will display and demonstrate products and technologies from the company's arrhythmia management portfolio at the 15th annual Boston Atrial Fibrillation (BAF) Symposium. The featured products reflect the company's continued commitment to the treatment of abnormal heart rhythms, including Atrial Fibrillation (AF). St. Jude Medical will feature products and technologies that aid physicians in the diagnosis and treatment of cardiac arrhythmias and cardiovascular disease in the U.S. and around the globe. Physicians can also get hands-on experience with several of the company's latest products by visiting the stations at the company's booths.
MAQUET Cardiovascular Announces Long-Term Follow-Up Data From Landmark 'SMART' Study Reinforce Positive Results For Patients Undergoing OPCAB
MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, announced that long-term results from the landmark SMART (Surgical Management of Arterial Revascularization) study will be presented tomorrow to attendees of the Society of Thoracic Surgeons's 46th Annual Meeting by John Puskas, M.D., Chief of Cardiac Surgery, Emory Crawford Long Hospital, Associate Chief of Cardiothoracic Surgery, Emory University, and SMART Study lead investigator. The data provide confirmation of the efficacy of performing Coronary Artery Bypass Graft surgery (CABG) while the patient's heart continues to beat a procedure known as Off-Pump Coronary Artery Bypass (OPCAB).
In a significant development for congenital heart disease patients, Medtronic, Inc. (NYSE: MDT), announced today that its Melody® Transcatheter Pulmonary Valve has received U.S. Food and Drug Administration (FDA) approval under a Humanitarian Device Exemption (HDE). This innovative medical device is the first transcatheter heart valve to receive FDA approval. Delivered through a catheter requiring only a small incision, the Melody valve will benefit children and adults who are born with a malformation of their pulmonary valve, which is the valve between the heart and lungs. These patients often require open-heart surgery to restore effective blood flow to their lungs.
Congenital heart defects (CHD) are the most common birth defects in humans, affecting 8 per 1000 live births with one-third of affected children requiring intervention in early infancy. Increasing numbers of survivors combined with developmental expectations for independence, behavioral self-regulation and academic achievement have led to a growing identification of neurobehavioral symptoms in some survivors. A study now suggests that a cooling technique often used in heart operations does not impair neurological outcomes. Congenital heart disease and its treatment were originally thought to potentially increase neurologic injury in these patients.
Yang Cao, an assistant professor in the computer science department at Virginia Tech's College of Engineering, has won a $550, 000 National Science Foundation Faculty Early Career Development (CAREER) award to develop computer simulation methods that will better understand the complex, discrete, and stochastic cell cycle model. The CAREER grant is the National Science Foundation's most prestigious award, given to creative junior faculty likely considered to become academic leaders of the future. The five-year grant funds Cao's (http://www.cs.vt.edu/user/31) research project, titled "Multi-scale Stochastic Simulation for Complex Biochemical Systems with Visualization Tools.
Cardium Provides Update On Commercial Development Plans For Generx Angiogenic Therapy For Heart Disease At 2010 Cell Gene Therapy Forum
Cardium Therapeutics (NYSE Amex: CXM) reported that its Cardium Biologics division provided an update on plans for the continuing commercial development of Generx™ (alferminogene tadenovec, Ad5FGF-4), a DNA-based angiogenic therapy product candidate for patients with coronary artery disease. The update was presented by Gabor M. Rubanyi, M.D., Ph.D., Cardium's Chief Scientific Officer at the annual 2010 Cell & Gene Therapy Forum in Washington, D.C. on January 25, 2010. Cardium Biologics reported on the following findings and plans: (1) As previously announced, based on an agreement with the FDA, Generx would be re-formulated to increase its shelf life, and further formulation enhancements are expected to allow for storage using a standard freezer (rather than at -70 degrees C), and potentially a lyophilized version for refrigerated storage.